Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system

Proprotein convertase subtilisin kexin type 9 (PCSK9) is a liver secretory enzyme that controls plasma low-density lipoprotein cholesterol (LDL-C) levels through modulation of LDL receptor (LDLR). Inhibition of PCSK9 using monoclonal antibodies (mAbs) can efficiently lower plasma LDL-C. However, the relatively short half-life of mAbs necessitates frequent passive immunization, which is costly. These limitations can be circumvented by active immunization. Here, we evaluated the long-term antiPCSK9 antibody generation in BALB/c mice vaccinated with a nanoliposomal PCSK9-specific active vaccine.

Source: Atherosclerosis - February 13, 2019 Category: Cardiology Authors: Amir Abbas Momtazi-Borojeni, Mahmoud Reza Jaafari, Ali Badiee, Amirhossein Sahebkar Source Type: research